The Care and Management of Bisphosphonate – Associated Osteonecrosis of the Jaw in the Patient with Multiple Myeloma: A Case Study

References

1. ↵
   1. Hose D,
   2. Rème T,
   3. Hielscher T,
   4. et al

   . Proliferation is a central independent prognostic factor and target for personalized and risk–adapted treatment in multiple myeloma. Haematologica. 2011;96(1):87–95.

   OpenUrlAbstract/FREE Full Text
2. ↵
   Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment: Health Professional Version. National Cancer Institute [Internet]. [cited 2011 April 4]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient
3. ↵
   1. Goldman L,
   2. Bennett CL

   1. Kyle RA

   . Plasma cell disorder: Hematologic Diseases. In: Goldman L, Bennett CL. Cecil Textbook of Medicine. 21st ed. Philadelphia: WB Saunders Company; 2000. p. 977–980.
4. ↵
   1. American Dental Association Council on Scientific Affairs

   . Professionally applied topical fluoride: Evidence–based clinical recommendations. J Am Dent Assoc. 2006;137(8):1151–1159.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Walter C,
   2. Al–Nawas B,
   3. Frickhofen N,
   4. et al

   . Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med. 2010;6:11.

   OpenUrlPubMed
6. ↵
   What you need to know about multiple myeloma. National Cancer Institute [Internet]. [cited 2008 Nov 16]. Available from: http://www.cancer.gov/cancertopics/wyntk/myeloma
7. ↵
   1. Vieira–Leite–Segundo A,
   2. Lima Falcão MF,
   3. Correia–Lins Filho R,
   4. Marques Soares MS,
   5. López López J,
   6. Chimenos Küstner E

   . Multiple Myeloma with primary manifestation in the mandible: A case report. Med Oral Patol Oral Cir Bucal. 2008;13(4):232–234.

   OpenUrl
8. ↵
   1. Ruggiero SL,
   2. Dodson TB,
   3. Assael LA,
   4. et al

   . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate–related osteonecrosis of the jaws––2009 update. J Oral Maxillofac Surg. 2009;67(5):2–12.

   OpenUrlPubMedWeb of Science
9. ↵
   1. Pickett FA,
   2. American Academy of Oral Medicine

   . Bisphosphonate–associated osteonecrosis of the jaw: A literature review and clinical practice guidelines. J Dent Hyg. 2006;80(3):10.

   OpenUrlFREE Full Text
10. ↵
    1. Badros A,
    2. Weikel D,
    3. Salama A,
    4. et al

    . Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2006:24(6):945–952.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Migliorati CA,
    2. Casiglia J,
    3. Epstein J,
    4. Jacobsen PL,
    5. Siegel MA,
    6. Woo SB

    . Managing the care of patients with bisphosphonate–associated osteonecrosis. An American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136(12):1658–1668.

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. Walter C,
    2. Al–Nawas B,
    3. Grötz KA,
    4. et al

    . Prevalence and risk factors of bisphosphonate–associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008;54(5):1066–1072.

    OpenUrlCrossRefPubMed
13. ↵
    1. Bagan JV,
    2. Jimenez Y,
    3. Murillo J,
    4. et al

    . Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42(3):327–329.

    OpenUrlCrossRefPubMedWeb of Science
14. 1. Bamias A,
    2. Kastritis E,
    3. Bamia C,
    4. et al

    . Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580–8587

    OpenUrlAbstract/FREE Full Text
15. 1. Mavrokokki T,
    2. Cheng A,
    3. Stien B,
    4. Goss A

    . Nature and frequency of bisphosphonate–associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415–423

    OpenUrlCrossRefPubMedWeb of Science
16. 1. Woo SB,
    2. Hellstein JW,
    3. Kalmar JR

    : Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–761.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Aragon–Ching JB,
    2. Ning YM,
    3. Chen CC,
    4. et al

    . Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti–angiogenic agents. Cancer Invest. 2009;27(2):221–226.

    OpenUrlCrossRefPubMedWeb of Science
18. 1. Boonyapakorn T,
    2. Schirmer I,
    3. Reichart PA,
    4. Sturm I,
    5. Massenkeil G

    . Bisphosphonate–induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44(9):857–869.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Advisory Task Force on Bisphosphonate–Related Ostenonecrosis of the Jaws,
    2. American Association of Oral and Maxillofacial Surgeons

    . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate–related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–376.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Borrás–Blasco J,
    2. Rosique–Robles D,
    3. Giner–Marco V,
    4. Galan–Brotons A,
    5. Casterá E,
    6. Costa S

    . Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid. A case report. J Clin Pharm Ther. 2007;32(6):651–654.

    OpenUrlCrossRefPubMed
21. ↵
    1. Goffinet M,
    2. Thoulouzan M,
    3. Pradines A,
    4. et al

    . Zoledronic acid treatment impairs protein geranyl–geranylation for biological effects in prostatic cells. BMC Cancer. 2006;6:60.

    OpenUrlCrossRefPubMed
22. 1. Luckman SP,
    2. Hughes DE,
    3. Coxon FP,
    4. Graham R,
    5. Russell G,
    6. Rogers MJ

    . Nitrogen–containing bisphosphonates inhibit the mevalonate pathway and prevent post–translational prenylation of GTP–binding proteins, including ras. J Bone Miner Res. 1998;13(4):581–589

    OpenUrlCrossRefPubMedWeb of Science
23. 1. Sedghizadeh PP,
    2. Kumar SK,
    3. Gorur A,
    4. Schaudinn C,
    5. Shuler CF,
    6. Costerton JW

    . Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66(4):767–775.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    1. Weitzman R,
    2. Sauter N,
    3. Eriksen EF,
    4. et al

    . Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients––May 2006. Crit Rev Oncol Hematol. 2007;62(2):148–152.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Taylor KH,
    2. Middlefell LS,
    3. Mizen KD

    . Osteonecrosis of the jaws induced by anti–RANK ligand therapy. Br J Oral Maxillofac Surg. 48(3):221–223.
26. 1. Kyrgidis A,
    2. Toulis KA

    . Denosumab–related osteonecrosis of the jaws. Osteoporos Int. 2011;22(1):369–370.

    OpenUrlCrossRefPubMed
27. 1. Aghaloo TL,
    2. Felsenfeld AL,
    3. Tetradis S

    . Osteonecrosis of the jaw in a patient on Denosumb. J Oral Maxillofac Surg. 2010;68(5):959–963.

    OpenUrlCrossRefPubMedWeb of Science
28. 1. Migliorati CA,
    2. Covington JS 3rd.

    . New oncology drugs and osteonecrosis of the jaw (ONJ). J Tenn Dent Assoc. 2009;89(4):36–38.

    OpenUrlPubMed
29. ↵
    1. Estilo CL,
    2. Fornier M,
    3. Farooki A,
    4. Carlson D,
    5. Bohle G 3rd.,
    6. Huryn JM

    . Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26(24):4037–4038.

    OpenUrlFREE Full Text
30. ↵
    1. Hellstein JW,
    2. Adler RA,
    3. Edwards B,
    4. et al

    . Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243–1251.

    OpenUrlAbstract/FREE Full Text
31. ↵
    1. Ripamonti CI,
    2. Maniezzo M,
    3. Campa T,
    4. et al

    . Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137–145.

    OpenUrlAbstract/FREE Full Text
32. ↵
    1. Dimopoulos MA,
    2. Kastritis E,
    3. Bamia C,
    4. et al

    . Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117–120.

    OpenUrlAbstract/FREE Full Text
33. ↵
    1. Khosla S,
    2. Burr D,
    3. Cauley J,
    4. et al

    . Bisphosphonate–Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1491.

    OpenUrlCrossRefPubMedWeb of Science